Relay Therapeutics Inc
RLAY6.050USD
-0.480-7.35%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
1.04BCap. mercado
PérdidaP/E TTM
Más Datos de Relay Therapeutics Inc Compañía
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Información de Relay Therapeutics Inc
Símbolo de cotizaciónRLAY
Nombre de la empresaRelay Therapeutics Inc
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoDr. Sanjiv K. Patel, M.D.
Número de empleados261
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección60 Hampshire Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02139
Teléfono16173708837
Sitio Webhttps://relaytx.com/
Símbolo de cotizaciónRLAY
Fecha de salida a bolsaJul 16, 2020
Director ejecutivoDr. Sanjiv K. Patel, M.D.
Ejecutivos de Relay Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
677.00K
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 8 de nov
Actualizado: sáb., 8 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
16.10%
Point72 Asset Management, L.P.
7.76%
Commodore Capital LP
7.70%
Casdin Capital, LLC
6.58%
BlackRock Institutional Trust Company, N.A.
6.13%
Otro
55.73%
Accionistas
Accionistas
Proporción
SB Investment Advisers (UK) Limited
16.10%
Point72 Asset Management, L.P.
7.76%
Commodore Capital LP
7.70%
Casdin Capital, LLC
6.58%
BlackRock Institutional Trust Company, N.A.
6.13%
Otro
55.73%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
34.94%
Investment Advisor
27.34%
Private Equity
16.87%
Investment Advisor/Hedge Fund
14.05%
Research Firm
1.95%
Individual Investor
1.32%
Venture Capital
1.04%
Sovereign Wealth Fund
0.48%
Family Office
0.44%
Otro
1.57%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SB Investment Advisers (UK) Limited
27.90M
16.19%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
13.45M
7.8%
+2.62M
+24.19%
Jun 30, 2025
Commodore Capital LP
13.35M
7.74%
+3.35M
+33.50%
Jun 30, 2025
Casdin Capital, LLC
11.40M
6.61%
+2.30M
+25.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.63M
6.16%
-159.25K
-1.48%
Jun 30, 2025
The Vanguard Group, Inc.
9.35M
5.42%
-2.73M
-22.57%
Jun 30, 2025
Bellevue Asset Management AG
8.23M
4.77%
+853.58K
+11.57%
Jun 30, 2025
Tang Capital Management, LLC
8.07M
4.68%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.20M
3.02%
+43.60K
+0.85%
Jun 30, 2025
Nextech Invest, Ltd.
3.85M
2.23%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
1.09%
Tema Oncology ETF
0.61%
ALPS Medical Breakthroughs ETF
0.53%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
Avantis US Small Cap Equity ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.06%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.09%
Tema Oncology ETF
Proporción0.61%
ALPS Medical Breakthroughs ETF
Proporción0.53%
SPDR S&P Biotech ETF
Proporción0.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.11%
Avantis US Small Cap Equity ETF
Proporción0.1%
ProShares Ultra Nasdaq Biotechnology
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.09%
iShares Biotechnology ETF
Proporción0.06%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
